Cardiac Implantable Electronic Devices Market Set for Steady Growth to Reach USD 21.7 Billion by 2030, Driven by Rising Cardiovascular Disease Burden and Technological Advancements

The Global Cardiac Implantable Electronic Devices (CIED) Market reached US$ 13.84 billion in 2022 and is projected to reach US$ 21.7 billion by 2030, growing at a CAGR of 5.8% during the forecast period 2023-2030. This sustained growth is fueled by the rising global prevalence of cardiac arrhythmias and other cardiovascular diseases, coupled with continuous product innovations and regulatory approvals for advanced devices like leadless pacemakers and MRI-conditional systems.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cardiac-implantable-electronic-devices-market?jd

North America Key Industry Developments (Largest Region)
• May 2025: Medtronic announced the first U.S. implants of its Aurora EV-ICD system following FDA approval. This next-generation defibrillator places the lead outside the heart and veins, potentially reducing long-term complications and represents a significant product launch in the largest market. [Source: Medtronic Newsroom]
• April 2025: Boston Scientific received FDA Breakthrough Device Designation for its next-generation EMBLEMTM MRI Subcutaneous Implantable Defibrillator (S-ICD) System with improved arrhythmia discrimination algorithms. This designation speeds up the development and review of technologies for life-threatening conditions. [Source: Boston Scientific News]
• March 2025: A study published in JACC: Clinical Electrophysiology demonstrated significant cost savings and reduced hospital visits using Abbott's Quadra AssuraTM CRT-D device with its HeartLogicTM diagnostic for proactive heart failure monitoring, strengthening the value proposition for advanced CIEDs in the U.S. healthcare system.

Asia-Pacific Key Industry Developments (Fastest Growing Region)
• June 2025: MicroPort Scientific launched its "Firefox" series of MRI-conditional pacemakers in several Southeast Asian markets, targeting cost-conscious healthcare systems with a technologically advanced product, intensifying regional competition.
• May 2025: Japan's Ministry of Health, Labour and Welfare (MHLW) expanded reimbursement for remote monitoring of CIEDs, encouraging the adoption of digital health platforms from companies like Biotronik and Abbott, which is expected to improve patient management and drive device uptake.
• April 2025: Lepu Medical (China) initiated a large-scale post-market surveillance study for its latest dual-chamber pacemaker, aiming to collect robust clinical data to support future regulatory submissions in international markets like Europe.

Key Mergers and Acquisitions (2025):
✅ Boston Scientific Acquires Preventice Solutions: In February 2025, Boston Scientific Corporation entered into a definitive agreement to acquire Preventice Solutions, Inc., a leader in ambulatory cardiac monitoring, from Hillrom. This $925 million strategic move aims to create a comprehensive heart rhythm management portfolio by combining Boston Scientific's implantable devices with Preventice's extensive outpatient diagnostic and monitoring technologies.
✅ Medtronic Acquires Aziyo Biologics' Cardiac Patch Business: In March 2025, Medtronic plc completed the acquisition of the cardiac patch business of Aziyo Biologics, Inc. for approximately $75 million. The acquisition centers on the CanGaroo® RM biologic envelope, a product designed to improve the integration of cardiac implants and reduce postoperative complications, enhancing the safety profile of Medtronic's pacemaker and ICD systems.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=cardiac-implantable-electronic-devices-market
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis
-By Product: Implantable Cardioverter Defibrillators (ICDs) Lead in Market Share
The Implantable Cardioverter Defibrillators (ICDs) segment, including transvenous and subcutaneous types, is expected to hold a dominant market share. This leadership is driven by continuous product launches and approvals for advanced systems, such as Abbott's Gallant line and Medtronic's extravascular (EV) ICD system, which offer life-saving therapy for patients at risk of sudden cardiac arrest.
Pacemakers, including single, dual-chamber, and biventricular (CRT-P) devices, form the foundation of the market. Innovation here is focused on miniaturization (e.g., leadless Micra devices) and enhanced compatibility (e.g., MRI-conditional systems), expanding safe treatment options for patients with bradycardia and heart failure.

-By Indication: Arrhythmia is the Primary Driver
Arrhythmias, particularly atrial fibrillation (AFib), represent the core indication driving CIED demand. With an estimated global prevalence of 37.6 million cases and projections of significant increase in the U.S. and Europe, the need for devices to monitor and manage irregular heartbeats is substantial.
Heart Failure and Block are critical indications addressed by Cardiac Resynchronization Therapy (CRT) devices and advanced pacemakers. These devices help improve the heart's pumping efficiency and correct electrical conduction delays, directly addressing the symptoms and progression of heart failure.

-By End-User: Hospitals are the Central Hub
Hospitals remain the primary end-user for CIED procedures, given the requirement for sophisticated surgical facilities, specialized electrophysiology labs, and comprehensive post-operative care for device implantation.
Ambulatory Surgery Centers (ASCs) and Specialty Clinics are growing segments, particularly for follow-up device monitoring and the implantation of less invasive devices. The pandemic accelerated the adoption of remote monitoring technologies, enabling more care to be managed efficiently outside traditional hospital settings.

Growth Drivers:
1. Rising Global Burden of Cardiovascular Diseases: Increasing prevalence of conditions like atrial fibrillation, heart failure, and the risk of sudden cardiac arrest creates a structural, growing patient pool requiring CIEDs.
2. Continuous Technological Innovation: Advancements such as leadless pacemakers, MRI-conditional devices, subcutaneous ICDs, and extravascular ICD systems improve safety, efficacy, and patient eligibility for implantation.
3. Favorable Regulatory Approvals and Product Launches: Consistent CE Mark and FDA approvals for next-generation devices (e.g., Biotronik's LBBP pacemakers, Medtronic's Aurora EV-ICD) quickly translate new technologies into commercial availability.
4. Expansion in High-Growth Asia-Pacific Markets: Strategic product launches and local partnerships in countries like India and China are making advanced therapies accessible in regions with large, underserved patient populations.
5. Integration of Remote Monitoring and Digital Health: The pandemic cemented the value of remote CIED management, improving patient follow-up and enabling proactive care, which supports market growth and patient outcomes.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cardiac-implantable-electronic-devices-market?jd

Regional Insights
North America is the largest market, attributed to its high healthcare expenditure, advanced healthcare infrastructure, strong reimbursement frameworks, and a significant patient base affected by cardiovascular diseases. The region is also a primary hub for clinical research and the first launch for many innovative devices.
Asia-Pacific is the fastest-growing market. Growth is fueled by improving healthcare access, rising medical tourism, increasing awareness of arrhythmia management, growing investments by global players, and the expanding middle-class population in countries like China and India.

Key Players:
The major global players in the market include Abbott, Medtronic plc, Boston Scientific Corporation, Biotronik AG, Stryker, Microport Scientific Corporation, Koninklijke Philips N.V., Lepu Medical Technology (Beijing) Co., Ltd., MEDICO S.R.L., and Vitatron among others.

Key Highlights (Top 5 Key Players):
1. Medtronic plc is a global leader with one of the broadest CIED portfolios, spanning pacemakers (including the revolutionary Micra leadless system), ICDs, and CRT devices. Its strength lies in continuous R&D, a robust global commercial footprint, and pioneering work in extravascular ICD technology.
2. Abbott Laboratories is a powerhouse in the cardiovascular space, offering a comprehensive line of CIEDs under brands like Assurity, Gallant, and CardioMEMS. Its strong focus on connected care through its Merlin.net remote monitoring platform integrates device data into patient management ecosystems.
3. Boston Scientific Corporation is a key innovator, particularly in MRI-conditional technology and subcutaneous ICDs (S-ICD). Its EMPOWER and ACUITY leads and the EMBLEM S-ICD System provide important alternatives for patients who may not be candidates for traditional transvenous systems.
4. Biotronik AG is recognized for its high-quality, innovative devices, especially in pacing therapy. It achieved a milestone with the first CE-marked pacemaker and CRT-P devices designed for Left Bundle Branch Area Pacing (LBBAP), a more physiological approach to cardiac resynchronization.
5. MicroPort Scientific Corporation is a prominent and fast-growing player from China, challenging established giants. Its focus on developing competitive electrophysiology devices for the domestic and emerging markets makes it a significant force shaping the competitive landscape in the Asia-Pacific region.

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply-Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.